Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis

Rinat Lifshiz Zimon; Galya Lerman; Einat Elharrar; Tal Meningher; Aviv Barzilai; Moamen Masalha; Ramesh Chintakunta; Etili Hollander; Riki Goldbart; Tamar Traitel; Moti Harats; Yechezkel Sidi; Dror Avni; Joseph Kost

doi:10.1016/j.jconrel.2018.05.040

Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis

Rinat Lifshiz Zimon
, Galya Lerman
, Einat Elharrar
, Tal Meningher
, Aviv Barzilai
, Moamen Masalha
, Ramesh Chintakunta
, Etili Hollander
, Riki Goldbart
, Tamar Traitel
, Moti Harats
, Yechezkel Sidi
, Dror Avni
, Joseph Kost

Department of Chemical Engineering

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

Psoriasis is a common, worldwide autoinflammatory, incurable skin disease. miR-197 has therapeutic potential for psoriasis since it can down-regulate the expression of both IL-22RA1 and IL-17RA, subunits of the receptors of IL-22 and IL-17, respectively, which are key cytokines in the disease. Although miR-197 has the potential to treat the disease, several inherent physical barrier properties of the skin challenge miRNA's delivery to the target skin cells. In the present study, we evaluated a therapeutic approach that combines the use of ultrasound (US) as a means to enhance skin permeability with quaternized starch (Q-starch) as an miRNA delivery carrier. This resulted in decreased expression of the miR-197 target proteins and in a significant reduction in the psoriatic activity markers. Our results demonstrate the potential of combinations of US and Q-starch/miR-197 complexes for the topical skin treatment of psoriasis.

Original language	English
Pages (from-to)	103-111
Number of pages	9
Journal	Journal of Controlled Release
Volume	284
DOIs	https://doi.org/10.1016/j.jconrel.2018.05.040
State	Published - 28 Aug 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Psoriasis
Starch
Topical gene delivery
Transdermal
Ultrasound
miR-197

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1016/j.jconrel.2018.05.040

Cite this

Lifshiz Zimon, R., Lerman, G., Elharrar, E., Meningher, T., Barzilai, A., Masalha, M., Chintakunta, R., Hollander, E., Goldbart, R., Traitel, T., Harats, M., Sidi, Y., Avni, D., & Kost, J. (2018). Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis. Journal of Controlled Release, 284, 103-111. https://doi.org/10.1016/j.jconrel.2018.05.040

@article{6f0ca53f849f42d5bf35e9ab71bd5e96,

title = "Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis",

abstract = "Psoriasis is a common, worldwide autoinflammatory, incurable skin disease. miR-197 has therapeutic potential for psoriasis since it can down-regulate the expression of both IL-22RA1 and IL-17RA, subunits of the receptors of IL-22 and IL-17, respectively, which are key cytokines in the disease. Although miR-197 has the potential to treat the disease, several inherent physical barrier properties of the skin challenge miRNA's delivery to the target skin cells. In the present study, we evaluated a therapeutic approach that combines the use of ultrasound (US) as a means to enhance skin permeability with quaternized starch (Q-starch) as an miRNA delivery carrier. This resulted in decreased expression of the miR-197 target proteins and in a significant reduction in the psoriatic activity markers. Our results demonstrate the potential of combinations of US and Q-starch/miR-197 complexes for the topical skin treatment of psoriasis.",

keywords = "Psoriasis, Starch, Topical gene delivery, Transdermal, Ultrasound, miR-197",

author = "\{Lifshiz Zimon\}, Rinat and Galya Lerman and Einat Elharrar and Tal Meningher and Aviv Barzilai and Moamen Masalha and Ramesh Chintakunta and Etili Hollander and Riki Goldbart and Tamar Traitel and Moti Harats and Yechezkel Sidi and Dror Avni and Joseph Kost",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = aug,

day = "28",

doi = "10.1016/j.jconrel.2018.05.040",

language = "English",

volume = "284",

pages = "103--111",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis

AU - Lifshiz Zimon, Rinat

AU - Lerman, Galya

AU - Elharrar, Einat

AU - Meningher, Tal

AU - Barzilai, Aviv

AU - Masalha, Moamen

AU - Chintakunta, Ramesh

AU - Hollander, Etili

AU - Goldbart, Riki

AU - Traitel, Tamar

AU - Harats, Moti

AU - Sidi, Yechezkel

AU - Avni, Dror

AU - Kost, Joseph

PY - 2018/8/28

Y1 - 2018/8/28

N2 - Psoriasis is a common, worldwide autoinflammatory, incurable skin disease. miR-197 has therapeutic potential for psoriasis since it can down-regulate the expression of both IL-22RA1 and IL-17RA, subunits of the receptors of IL-22 and IL-17, respectively, which are key cytokines in the disease. Although miR-197 has the potential to treat the disease, several inherent physical barrier properties of the skin challenge miRNA's delivery to the target skin cells. In the present study, we evaluated a therapeutic approach that combines the use of ultrasound (US) as a means to enhance skin permeability with quaternized starch (Q-starch) as an miRNA delivery carrier. This resulted in decreased expression of the miR-197 target proteins and in a significant reduction in the psoriatic activity markers. Our results demonstrate the potential of combinations of US and Q-starch/miR-197 complexes for the topical skin treatment of psoriasis.

AB - Psoriasis is a common, worldwide autoinflammatory, incurable skin disease. miR-197 has therapeutic potential for psoriasis since it can down-regulate the expression of both IL-22RA1 and IL-17RA, subunits of the receptors of IL-22 and IL-17, respectively, which are key cytokines in the disease. Although miR-197 has the potential to treat the disease, several inherent physical barrier properties of the skin challenge miRNA's delivery to the target skin cells. In the present study, we evaluated a therapeutic approach that combines the use of ultrasound (US) as a means to enhance skin permeability with quaternized starch (Q-starch) as an miRNA delivery carrier. This resulted in decreased expression of the miR-197 target proteins and in a significant reduction in the psoriatic activity markers. Our results demonstrate the potential of combinations of US and Q-starch/miR-197 complexes for the topical skin treatment of psoriasis.

KW - Psoriasis

KW - Starch

KW - Topical gene delivery

KW - Transdermal

KW - Ultrasound

KW - miR-197

UR - https://www.scopus.com/pages/publications/85048704386

U2 - 10.1016/j.jconrel.2018.05.040

DO - 10.1016/j.jconrel.2018.05.040

M3 - Article

C2 - 29870766

AN - SCOPUS:85048704386

SN - 0168-3659

VL - 284

SP - 103

EP - 111

JO - Journal of Controlled Release

JF - Journal of Controlled Release

ER -

Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this